PharmSource has released an extensive study on the supply and demand for contract injectable manufacturing through 2019. The analysis provides information on the latest trends for outsourcing of commercially approved injectable products.
The report leverages PharmSource’s Strategic Advantage Database of Contract Service Providers and provides projections for key processing capabilities, including aseptic fill, lyophilized vials and prefilled devices such as syringes, cartridges and proprietary devices. The study analyzes the current capacity and planned capacity expansion of contract manufacturers, as well as the plans by major sponsors to increase in-house capacity.
The 80-page report has more than 25 tables and more than 20 charts and graphs that illustrate major points and trends. This report serves a resource for CMO, sourcing and procurement executives, as well as private equity investors, to understand the industry and strategic planning efforts, and provide insights for supplier selection and management, as well as identify potential investment targets.
Contract Pharma will feature a podcast conversation with PharmSource president Jim Miller in January 2014.